Filtros de búsqueda

Lista de obras de Brian G. Feagan

5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion

artículo científico publicado en 2004

A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials

artículo científico publicado en 2017

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease

scientific article published on 22 December 2019

A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty.

artículo científico publicado en 2007

A comparison of endoscopic and surgical treatment of strictures in patients with Crohn’s disease

artículo científico publicado en 2013

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

artículo científico publicado en 2000

A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score

article

A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

artículo científico publicado en 2001

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

artículo científico publicado en 2000

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease

artículo científico publicado en 2008

A phase II study of laquinimod in Crohn's disease

artículo científico publicado en 2014

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

artículo científico

A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease

artículo científico publicado en 2012

A randomized survey of the preference of gastroenterologists for a Cochrane review versus a traditional narrative review

artículo científico publicado en 2002

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

article

A randomized trial of arthroscopic surgery for osteoarthritis of the knee

artículo científico publicado en 2008

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

artículo científico publicado en 2005

A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis

artículo científico publicado en 2008

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

artículo científico publicado en 2014

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

artículo científico publicado en 2006

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

artículo científico publicado en 2002

A review of activity indices and end points for clinical trials in children with Crohn's disease

artículo científico publicado en 2005

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

artículo científico publicado en 2009

A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design

artículo científico publicado en 2014

A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research

artículo científico publicado en 2014

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab

artículo científico publicado en 2013

AGA technical review on perianal Crohn’s disease ⬇️

artículo científico publicado el 1 de noviembre de 2003

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease

artículo científico publicado en 2017

Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis

artículo científico publicado en 2013

Alicaforsen for the treatment of inflammatory bowel disease

artículo científico publicado en 2017

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

artículo científico publicado en 2007

Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease

artículo científico publicado en 1998

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease

artículo científico publicado en 2018

An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials

artículo científico publicado en 2021

An overview of magnetic resonance enterography for Crohn's disease

artículo científico

Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease

artículo científico publicado en 2019

Annual cost of care for Crohn's disease: a payor perspective

artículo científico publicado en 2000

Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?

artículo científico publicado en 2016

Anti-MAdCAM antibody for induction of remission in ulcerative colitis

artículo científico publicado en 2015

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

artículo científico

Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives

artículo científico publicado en 2016

Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews

artículo científico

Assessment of histologic disease activity in Crohn's disease: a systematic review

artículo científico publicado en 2014

Assessment of mucosal healing in inflammatory bowel disease: review.

artículo científico

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

artículo científico publicado en 2015

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis

artículo científico publicado en 2014

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

article published in 2017

Biosimilars in IBD: hope or expectation?

artículo científico

Biosimilars: State of Clinical and Regulatory Science

artículo científico publicado en 2017

Briakinumab for treatment of Crohn's disease: results of a randomized trial

artículo científico publicado en 2015

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

artículo científico publicado en 2005

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

artículo científico

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

artículo científico publicado en 2004

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

artículo científico publicado en 2006

Central Endoscopy Reading in Inflammatory Bowel Diseases

artículo científico publicado en 2016

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials

artículo científico

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study

artículo científico publicado en 2017

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

artículo científico publicado en 2011

Certolizumab pegol for the treatment of Crohn's disease

artículo científico publicado en 2007

Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease

artículo científico publicado en 2007

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease

artículo científico

Challenging question: is treating inflammatory bowel disease an art or strictly an evidence-based matter?

artículo científico

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

artículo científico publicado en 2009

Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus

artículo científico publicado en 2015

Clinical remission as defined by the Mayo Score: do we deceive ourselves?

artículo científico publicado en 2015

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease

artículo científico publicado en 2009

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

artículo científico publicado en 2009

Combination therapy for the treatment of Crohn's disease

artículo científico publicado en 2015

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

artículo científico publicado en 2002

Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.

artículo científico publicado en 2014

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

scientific article published on 01 February 2004

Converging goals of treatment of inflammatory bowel disease from clinical trials and practice

artículo científico publicado en 2014

Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease

artículo científico publicado en 2020

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

artículo científico publicado en 2018

Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease

artículo científico publicado en 2017

Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee

artículo científico publicado en 2016

Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD.

artículo científico publicado en 2014

Current issues in the design of clinical trials in IBD.

artículo científico publicado en 2014

Cyclosporine for induction of remission in Crohn's disease

artículo científico publicado en 2005

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

artículo científico publicado en 2006

Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort

scientific article published on 17 October 2019

Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

artículo científico publicado en 2016

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease

artículo científico publicado en 2008

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

artículo científico publicado en 2009

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease - an International, Cross-disciplinary Consensus.

artículo científico publicado en 2017

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

artículo científico publicado en 2011

Development and validation of a histological index for UC.

artículo científico publicado en 2015

Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.

artículo científico publicado en 2017

Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease.

artículo científico publicado en 2018

Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey

artículo científico

Development of an index to define overall disease severity in IBD.

artículo científico publicado en 2016

Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

artículo científico publicado en 2015

Development of the Crohn's disease digestive damage score, the Lémann score

artículo científico publicado en 2010

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process

artículo científico

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis

artículo científico publicado en 2020

Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials

artículo científico publicado en 2016

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Restaurantmanhaj's

artículo científico publicado en 2014

EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging

artículo científico publicado en 2013

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

artículo científico publicado en 2015

Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT

scientific article published on 19 March 2019

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

artículo científico publicado en 2008

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

artículo científico publicado en 2011

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

artículo científico

Editorial: aminosalicylates in Crohn's disease-prevalence, risks, costs and time to reassess? Authors' reply

artículo científico publicado en 2018

Editorial: evolving histological assessment of NASH. Authors' reply

scientific article published on 01 December 2019

Editorial: histologic normalisation in ulcerative colitis

scientific article published on 01 February 2020

Editorial: the impact of the placebo effect in Crohn's disease - author's reply.

artículo científico publicado en 2017

Editorial: treating strictures in inflammatory bowel disease-authors' reply

scientific article published on 01 December 2018

Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE-HSS)-an important first step. Authors' reply

scientific article published on 01 June 2018

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.

artículo científico publicado en 2017

Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease

artículo científico publicado en 2016

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.

artículo científico publicado en 2017

Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease

artículo científico publicado en 2017

Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease

scientific article published on 04 July 2019

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

artículo científico publicado en 2018

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

artículo científico publicado en 2008

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

artículo científico publicado en 2008

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy

artículo científico publicado en 2016

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

artículo científico publicado en 2014

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

artículo científico publicado en 2016

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis

scientific article published on 23 November 2018

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study

artículo científico publicado en 2017

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease

artículo científico publicado en 2020

Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis

artículo científico publicado en 2018

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease

artículo científico publicado en 2018

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

artículo científico publicado en 2016

Efficacy of vedolizumab in fistulising Crohn's disease: Exploratory analyses of data from GEMINI 2.

artículo científico publicado en 2018

Emerging Therapies for Inflammatory Bowel Diseases

artículo científico publicado en 2016

Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease

artículo científico publicado en 2013

Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease

artículo científico publicado en 2016

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis

artículo científico publicado en 2015

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis

artículo científico publicado en 2018

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

artículo científico publicado en 2009

Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview

artículo científico publicado en 2017

Erratum: Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Respo

article

Ethics of n-of-1 trials.

artículo científico publicado en 1995

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

artículo científico publicado en 2014

Etrolizumab for induction of remission in ulcerative colitis

artículo científico publicado en 2015

Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study

scientific article published on 27 September 2020

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol ⬇️

artículo científico publicado el 28 de marzo de 2011

Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease

scientific article published on 15 April 2019

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease

artículo científico publicado en 2009

Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions

artículo científico publicado en 2018

Evolving Concepts in Phases I and II Drug Development for Crohn's Disease

artículo científico publicado en 2016

Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease

artículo científico publicado en 2017

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

artículo científico publicado en 2017

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease

scientific article published on 01 May 2006

Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

artículo científico publicado en 2019

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

artículo científico publicado en 2010

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

artículo científico publicado en 2014

Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.

artículo científico publicado en 2012

Health-related quality of life during natalizumab maintenance therapy for Crohn's disease

artículo científico publicado en 2007

Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence

artículo científico publicado en 2014

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set.

artículo científico publicado en 2018

High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study

artículo científico publicado en 2004

Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices

artículo científico publicado en 2014

Histologic scoring indices for evaluation of disease activity in ulcerative colitis

artículo científico publicado en 2014

Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

artículo científico publicado en 2017

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease

scientific article published on 01 January 2020

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

artículo científico

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

artículo científico publicado en 2017

Inflammatory bowel disease: a Canadian burden of illness review

artículo científico publicado en 2012

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

artículo científico

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection

artículo científico publicado en 2016

Infliximab for induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2005

Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics

artículo científico publicado en 2001

Infliximab maintenance therapy for fistulizing Crohn's disease

artículo científico publicado en 2004

Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?

artículo científico publicado en 2002

Innovations in Oral Therapies for Inflammatory Bowel Disease

scientific article published on 01 August 2019

Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases

artículo científico publicado en 2016

Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease

scientific article published on 10 August 2018

Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply

artículo científico publicado en 2014

Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension

artículo científico publicado en 2018

Long-term Efficacy of Vedolizumab for Crohn's Disease

artículo científico publicado en 2016

Long-term Efficacy of Vedolizumab for Ulcerative Colitis

artículo científico publicado en 2016

Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease

artículo científico publicado en 2013

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

artículo científico publicado en 2018

Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies

scientific article published on 11 April 2011

Long-term safety of vedolizumab for inflammatory bowel disease

scientific article published on 02 September 2020

MRI scoring indices for evaluation of disease activity and severity in Crohn’s disease

artículo científico publicado en 2015

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

artículo científico publicado en 2002

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

artículo científico publicado en 2016

Maintenance therapy for inflammatory bowel disease

artículo científico publicado en 2003

Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility

artículo científico publicado en 2007

Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission

artículo científico publicado en 2007

Mesalamine maintenance therapy for Crohn's disease

artículo científico publicado en 2001

Methotrexate for induction of remission in refractory Crohn's disease

artículo científico publicado en 2014

Methotrexate for induction of remission in refractory Crohn's disease

artículo científico publicado en 2012

Methotrexate for induction of remission in refractory Crohn's disease

artículo científico publicado en 2004

Methotrexate for induction of remission in refractory Crohn's disease.

artículo científico publicado en 2003

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

artículo científico publicado en 2013

Methotrexate in inflammatory bowel disease

artículo científico publicado en 2004

Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study

scientific article published on 16 December 2019

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

artículo científico publicado en 2005

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

artículo científico publicado en 2007

New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?

artículo científico publicado en 2015

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease

artículo científico publicado en 2018

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα

OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials

artículo científico

Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis

artículo científico publicado en 2012

Optimising monitoring in the management of Crohn's disease: a physician's perspective

artículo científico publicado en 2013

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

artículo científico publicado en 2016

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis

artículo científico publicado en 2012

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

artículo científico publicado en 2016

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

artículo científico publicado en 2012

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

artículo científico publicado en 1994

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

artículo científico publicado en 2013

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

artículo científico publicado en 2016

Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data

artículo científico publicado en 2018

Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease

artículo científico publicado en 2017

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease

artículo científico publicado en 2018

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

scientific article published on 20 July 2016

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s disease

artículo científico publicado en 2016

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2017

Placebo response and remission rates in randomized trials of induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2015

Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis

scientific article published on 22 January 2020

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

artículo científico publicado en 2015

Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing

scientific article published on 09 August 2020

Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report

scientific article published on 19 July 2018

Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis

scientific article published on 22 November 2019

Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

artículo científico publicado en 2000

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

artículo científico publicado en 1994

Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis

scientific article published on 24 May 2016

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis

artículo científico publicado en 2015

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab ⬇️

artículo científico publicado el 12 de enero de 2011

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

artículo científico publicado en 2015

Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.

artículo científico publicado en 2017

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

artículo científico publicado en 2000

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report

artículo científico publicado en 2011

Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis

artículo científico publicado en 2020

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

artículo científico publicado en 2008

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis

Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease

artículo científico publicado en 2015

Reliability and initial validation of the ulcerative colitis endoscopic index of severity

artículo científico publicado en 2013

Reliability of EUS indices to detect inflammation in ulcerative colitis

artículo científico publicado en 2017

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease

scientific article published on 29 August 2019

Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography

artículo científico publicado en 2018

Reliability of histologic assessment in patients with eosinophilic oesophagitis.

artículo científico publicado en 2018

Reproducibility of histological assessments of disease activity in UC.

artículo científico publicado en 2014

Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis

scientific article published on 01 September 2007

Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease

artículo científico publicado en 2017

Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial

scientific article published on 03 August 2018

Review and clinical perspectives for the use of infliximab in ulcerative colitis

artículo científico publicado en 2008

Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy.

artículo científico publicado en 1997

Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life

artículo científico publicado en 1999

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm

artículo científico publicado en 2003

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis

artículo científico publicado en 2017

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

artículo científico

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

scientific article published on September 2008

Safety of biologics: current issues and future concerns.

artículo científico publicado en 2001

Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events

artículo científico

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

artículo científico publicado en 2012

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

artículo científico publicado en 2012

Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2).

artículo científico publicado en 2013

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials

artículo científico publicado en 2019

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.

artículo científico publicado en 2009

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

artículo científico publicado en 2013

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

artículo científico publicado en 2013

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

artículo científico publicado en 2019

Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis

artículo científico publicado en 2016

Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis

artículo científico publicado en 2017

Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease

artículo científico publicado en 2019

Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

artículo científico publicado en 2018

Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies

scientific article published on 19 December 2018

Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.

artículo científico publicado en 2017

Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

scientific article published on 30 May 2018

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

artículo científico publicado en 2018

Systematic review: medical therapy for fibrostenosing Crohn's disease

artículo científico publicado en 2020

T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects

artículo científico publicado en 2014

Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis

artículo científico publicado en 2008

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

artículo científico publicado en 2003

Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

artículo científico

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence

scientific article published on 10 September 2020

The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs

artículo científico publicado en 2017

The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].

artículo científico publicado en 2015

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

artículo científico publicado en 2010

The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews

artículo científico publicado en 2016

The challenge of indication extrapolation for infliximab biosimilars

artículo científico publicado en 2014

The development of a magnetic resonance imaging index for fistulising Crohn's disease

artículo científico publicado en 2017

The effectiveness of budesonide therapy for Crohn's disease

artículo científico publicado en 2002

The effects of infliximab maintenance therapy on health-related quality of life.

artículo científico publicado en 2003

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

artículo científico publicado en 2007

The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain

artículo científico publicado en 2004

The efficacy, safety and acceptance of autologous blood donation as a blood conservation strategy.

artículo científico publicado en 2002

The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?

artículo científico publicado en 2017

The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy

artículo científico

The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease

artículo científico publicado en 2014

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

artículo científico publicado en 2014

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis

artículo científico

The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review

scholarly article published in Saudi Journal of Gastroenterology

The safety of vedolizumab for the treatment of ulcerative colitis

artículo científico publicado en 2017

The safety of vedolizumab for ulcerative colitis and Crohn's disease

artículo científico publicado en 2016

Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease

artículo científico publicado en 2014

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives

artículo científico

Therapeutic drug monitoring of biologics for inflammatory bowel disease

artículo científico publicado en 2011

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

artículo científico publicado en 2012

Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials.

artículo científico publicado en 1996

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

artículo científico publicado en 2017

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

artículo científico publicado en 2017

Toward a personalized medicine approach to the management of inflammatory bowel disease

artículo científico

Transfusion practices for elective orthopedic surgery

artículo científico publicado en 2002

Treat to target: a proposed new paradigm for the management of Crohn's disease

artículo científico

Treatment and outcomes of community-acquired pneumonia at Canadian hospitals

artículo científico publicado en 2000

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

artículo científico publicado en 2008

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

artículo científico publicado en 2005

Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?

artículo científico publicado en 2014

Unemployment and disability in patients with moderately to severely active Crohn's disease

artículo científico publicado en 2005

Use of acetylsalicylic acid by physicians and in the community

artículo científico publicado en 1991

Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.

artículo científico publicado en 2001

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

artículo científico publicado en 2016

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

artículo científico publicado en 2012

Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort

artículo científico publicado en 2015

Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers

artículo científico publicado en 2016

Vedolizumab as induction and maintenance therapy for Crohn's disease

artículo científico publicado en 2013

Vedolizumab as induction and maintenance therapy for ulcerative colitis

artículo científico publicado en 2013

Vedolizumab for Crohn's disease

artículo científico publicado en 2013

Vedolizumab for induction and maintenance of remission in Crohn’s disease

artículo científico publicado en 2015

Vedolizumab for induction and maintenance of remission in ulcerative colitis

artículo científico publicado en 2014

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

artículo científico publicado en 2015

What do I do in my practice that isn't evidence based?

artículo científico publicado en 2002

What do changes in inflammatory bowel disease management mean for our patients?

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda